GlassScriptPhysician profile
Roy J Watts
NPI 1770699308
$2,592.70
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $362 · 2021: $1,048 · 2022: $574 · 2023: $121 · 2024: $78.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $199.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $305.54 | 2019-2023 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $183.36 | 2019-2022 | |
| Abbott Laboratories | $179.72 | 2019-2024 | Freestyle Libre 2, Octrode |
| Novartis Pharmaceuticals Corporation | $173.70 | 2019-2022 | |
| Daiichi Sankyo INC. | $172.23 | 2019-2021 | |
| Novo Nordisk INC | $171.45 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.28 | 2019-2022 | |
| Glaxosmithkline, LLC. | $136.17 | 2019-2022 | |
| Astellas Pharma US INC | $111.82 | 2019-2020 | |
| Pfizer INC. | $101.03 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $98.00 | 2021-2022 | |
| Lilly USA, LLC | $96.78 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $84.71 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $82.48 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $82.37 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $72.65 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.05 | 2020-2021 | |
| Boston Scientific Corporation | $52.41 | 2024 | Lux-Dx Insertable Cardiac Monitor |
| Allergan, INC. | $36.06 | 2019-2020 | |
| Nalu Medical, INC. | $33.64 | 2021 | |
| Sanofi Pasteur INC. | $33.23 | 2021 | |
| Amarin Pharma, INC. | $28.74 | 2019-2021 | |
| Mylan Specialty L.P. | $27.11 | 2022 | |
| Merck Sharp & Dohme LLC | $20.29 | 2021 | |
| Philips North America LLC | $16.80 | 2020 | |
| Nevro Corp. | $15.20 | 2022 | |
| Bardy Diagnostics, INC. | $15.20 | 2021 | |
| Apria Healthcare LLC | $14.48 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.10 | 2022 | |
| Smith+Nephew, INC. | $11.83 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Watts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.